Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — Investor Presentation (October 2026)
19 slides from Abeona Therapeutics's investor presentation, October 2026
Slide 1: Corporate Overview
Corporate Overview October 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempt
Slide 3: Pipeline of differentiated cell and gene therapies
Pipeline of differentiated cell and gene therapies PRECLINICAL PHASE 1/2 PHASE 3 / PIVOTAL APPROVED PSMA-SIR-T* Advanced Prostate Cancer UX111** Sales milestones, royalties PARTNERED Sanfilippo syndrome type A (MPS IIIA) TSHA-102*** Clinical, regulatory, sales Rett syndrome milestones, royalties Und
Slide 4: ZEVASKYN foundation for Abeona's growth
ZEVASKYN® foundation for Abeona’s growth Q2 2026 Highlights • Growing Qualified Treatment Center (QTC) network across US, where 40% of Net Product Revenue ($M) the addressable US market has in-state access to a QTC $12.0 $11.4 • 100+ patients have been identified across QTCs and non-QTC physicians •
Slide 5: RDEB is caused by lack of functional C7 protein, resulting in large, chronic wounds
RDEB is caused by lack of functional C7 protein, resulting in large, chronic wounds • Rare and debilitating condition caused by mutations in both copies of COL7A1 gene • RDEB wounds can lead to serious life-threatening complications – Years of large painful wounds, itch and infection – 90% risk of d
Slide 6: The only gene therapy that genetically modifies patient's own skin cells to treat wounds
The only gene therapy that genetically modifies patient's own skin cells to treat wounds in children & adults with RDEB • Single surgical treatment • Extensive coverage across multiple wound areas • Years of wound healing and pain relief in clinical studies Geovanna, a ZEVASKYN® patient at age 8 6
Slide 7: Up to 12 ZEVASKYN sheets can be applied in one surgical session
Up to 12 ZEVASKYN sheets can be applied in one surgical session ZEVASKYN sheets can be joined together to treat larger Two pea-sized wounds on patient’s front, back, or sides, (8 mm) biopsies or used individually for smaller wounds up to 12 ZEVASKYN sheets ZEVASKYN cellular sheet Up to 12 ZEVASKYN s
Slide 8: Example RDEB wounds before and after ZEVASKYN treatment
Example RDEB wounds before and after ZEVASKYN treatment Source: Phase 3 VIITAL study patient; wounds scored as at least 75% healing at week 24; individual results vary 8 Wound healing scoring was Investigator-assessed per predefined criteria.
Slide 9: EB patients already travel significant distances for specialized care
EB patients already travel significant distances for specialized care and have indicated willingness to travel for ZEVASKYN Referral Catchment Areas For Key EB COEs (2022-2023) 50 mi. 300 mi. 50 mi. 500 mi. 100 mi. Catchment area for nearest 70% of referrals • Roughly 40% of pts managed at EB COEs l
Slide 10: Expanding ZEVASKYN QTC network enhances patient access
Expanding ZEVASKYN QTC network enhances patient access NewYork-Presbyterian/ Columbia University Irving Medical Center Ann & Robert H. Lurie Stanford Medicine Children’s Hospital of Chicago Children's Health Children’s Hospital of Philadelphia Children's Hospital Cincinnati Children's Patient suppor
Slide 11: ZEVASKYN patient journey
ZEVASKYN patient journey Patient identify & Clinical prior Financial Biopsy & Hospital stay & ZEVASKYN authorizations clearance & ZEVASKYN discharge consult/decision scheduling manufacturing, surgery 1 2 3 4 5 Revenue recognized Average 3-4 months ~25 days 5-10 days (variable and dependent on patien
Slide 12: Example of wound healing from Phase 1/2a long term follow up
Example of wound healing from Phase 1/2a long term follow up Upper Back Patient during long term follow Patient at end of in-person Patient before treatment Patient after surgery up – year 2 long term follow up – year 5 All images shown are from the same patient; Individual results may vary. • Study
Slide 13: Case study example of the longest patient follow up of 12 years from Phase 1/2a
Case study example of the longest patient follow up of 12 years from Phase 1/2a Distal Right Forearm Patient during long term follow up Patient during long term follow up Patient during long term follow up Patient before treatment – Year 1 – Year 6 – Year 12 All images shown are from the same patien
Slide 14: Case study example of the longest patient follow up of 12 years from Phase 1/2a
Case study example of the longest patient follow up of 12 years from Phase 1/2a Right Deltoid Shoulder Patient during long term follow up Patient during long term follow up Patient during long term follow up Patient before treatment – Year 1 – Year 6 – Year 12 All images shown are from the same pati
Slide 15: Examples of wound healing at 5 years for Phase 3 patients
Examples of wound healing at 5 years for Phase 3 patients Individual results may vary Eid E et al. "Sustained wound healing and long-term safety of prademagenezamikeracel in recessive dystrophic epidermolysis bullosa (RDEB): five-year results from the VIITAL phase 3 trial". Society for Investigative
Slide 16: Significant U.S. commercial opportunity for ZEVASKYN
Significant U.S. commercial opportunity for ZEVASKYN ~1,300 U.S. DEB patients1; ~750 RDEB ZEVASKYN-eligible patients Anticipate average 2 treatment cycles per patient to cover impacted body areas (~1,500 treatment opportunities) $3.1M WAC per each treatment Strong early payer coverage and reimbursem
Slide 17: PSMA SIR-T for Advanced Prostate Cancer
Leveraging cell therapy core competencies to advance a novel pipeline PSMA SIR-T for Advanced Prostate Cancer 17
Slide 18: PSMA SIR-T (ABO-701) has the potential to unlock cell therapy for prostate cancer patients
PSMA SIR-T (ABO-701) has the potential to unlock cell therapy for prostate cancer patients with a high unmet need • PSMA is a validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles • PSMA SIR-T i
Slide 19: Anchored by ZEVASKYN and unique capabilities, Abeona is poised for growth
Anchored by ZEVASKYN and unique capabilities to commercialize complex genetic medicines, Abeona is poised for growth Significant support $11.4M net product Pipeline solid tumor of ZEVASKYN from revenue in Q2 2026, oncology PSMA RDEB community 31% quarter-over- program represents a and commercial qua
Abeona Therapeutics — Investor Presentation (October 2026) on 6ix